Cargando…
Efficacy of cognitive enhancers for Alzheimer’s disease: protocol for a systematic review and network meta-analysis
BACKGROUND: Approximately 35 million people world-wide have Alzheimer’s disease and this is projected to nearly double by 2030. Cognitive enhancers, including cholinesterase inhibitors (for example, donepezil, galantamine and rivastigmine) and memantine (N-methyl-D-aspartic acid (NMDA) receptor anta...
Autores principales: | Tricco, Andrea C, vanderVaart, Sondra, Soobiah, Charlene, Lillie, Erin, Perrier, Laure, Chen, Maggie H, Hemmelgarn, Brenda, Majumdar, Sumit R, Straus, Sharon E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407718/ https://www.ncbi.nlm.nih.gov/pubmed/22742585 http://dx.doi.org/10.1186/2046-4053-1-31 |
Ejemplares similares
-
Use of cognitive enhancers for mild cognitive impairment: protocol for a systematic review and network meta-analysis
por: Tricco, Andrea C, et al.
Publicado: (2012) -
Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: protocol for a systematic review and network meta-analysis
por: Tricco, Andrea C, et al.
Publicado: (2013) -
Safety, effectiveness, and cost of long-acting versus intermediate-acting insulin for type 1 diabetes: Protocol for a systematic review and network meta-analysis
por: Tricco, Andrea C, et al.
Publicado: (2013) -
What is the most appropriate knowledge synthesis method to conduct a review? Protocol for a scoping review
por: Kastner, Monika, et al.
Publicado: (2012) -
Impact of H1N1 on Socially Disadvantaged Populations: Systematic Review
por: Tricco, Andrea C., et al.
Publicado: (2012)